No phaseCompleted
Vaginal Prasterone Versus Estriol in Women With Pelvic Floor Disorders
Short-Term Vaginal Estriol Versus Prasterone in Women With Pelvic Floor Disorders: A Prospective Non-Randomized Comparative Study of Symptoms and Quality of Life"
- Sponsor
- Poznan University of Medical Sciences (Academic or other)
- Enrolment
- 74 enrolled
- Conditions
- Pelvic Organ Prolapse (POP); Stress Urinary Incontinence (SUI)
- Interventions
- Prasterone (DHEA); Estriol
- Ages
- adults, older adults
- Registry
- NCT07854873
From the registry
This prospective, non-randomized comparative study evaluated the effects of short-term vaginal treatment with prasterone or estriol in women with pelvic floor disorders who were awaiting urogynecological surgery. A total of 74 women were included, with 37 participants receiving vaginal prasterone and 37 receiving vaginal estriol. Treatment was administered before surgery for approximately 8 weeks. The study assessed changes in pelvic floor symptoms and quality of life using the WHOQOL-BREF questionnaire and symptom severity scales. The aim was to compare the effects of the two vaginal treatments on symptoms and quality of life before urogynecological surgery.
Primary outcomes
- Change in Quality of Life Measured by WHOQOL-BREF